Sundaram Sridhar, Mane Kiran, Patil Prachi, Rathod Raosaheb, Jain Aadish Kumar, Tyagi Unique, Mehta Shaesta
Department of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Mumbai, India.
Homi Bhabha National Institute, Parel, Mumbai, 400012, India.
Dig Dis Sci. 2023 Apr;68(4):1551-1558. doi: 10.1007/s10620-022-07655-w. Epub 2022 Aug 10.
No large studies have addressed the role of endoscopic-ultrasound biliary drainage (EUS-BD) as preoperative biliary drainage (PBD) for malignant extrahepatic biliary obstruction (MEBO). We aimed to discuss the outcomes of EUS antegrade stent placement (EUS-AG) in the preoperative and palliative setting.
Retrospective review of patients who underwent EUS-AG for MEBO between December 2019 and December 2021 was done. Primary outcome measures were technical success and clinical success. Secondary outcome measures were number of days of hospitalization postprocedure, adverse events related to EUS-AG procedure, morbidity related to surgery, and 3-month mortality after surgery.
54 patients underwent attempt for EUS-AG (mean age 54.8 ± 12.1 years; female 44.4%). Most common primary cancer was pancreatic cancer in 42.1% (23/54) patients. Indication was palliative in 34 (62.9%) patients and PBD in 20 (37%) patients. Level of block was distal in 35 (64.8%) and proximal in 19 (35.1%) patients. Technical success of EUS-AG was 88.7% (47/53). Clinical success was seen in 95.7% (45/47) patients. Median number of days of hospitalization postprocedure was 1 day. No procedure-related severe adverse events were seen. Of 20 patients who underwent EUS-AG as PBD, 19 had technical success (95%) with clinical success in 94.5% (18/19). Surgery was performed in 11 patients, of whom 10 patients underwent successful PPPD (one intraoperative liver metastasis). Two patients had Clavein-Dindo III/IV complication post-PPPD, with one mortality within 30 days of surgery.
EUS-AG is safe and effective after failed ERCP in both preoperative and palliative setting.
尚无大型研究探讨内镜超声引导下胆道引流(EUS-BD)作为恶性肝外胆管梗阻(MEBO)术前胆道引流(PBD)的作用。我们旨在探讨术前及姑息治疗中内镜超声引导下顺行支架置入术(EUS-AG)的效果。
对2019年12月至2021年12月期间因MEBO接受EUS-AG治疗的患者进行回顾性分析。主要观察指标为技术成功率和临床成功率。次要观察指标为术后住院天数、与EUS-AG操作相关的不良事件、手术相关并发症及术后3个月死亡率。
54例患者尝试行EUS-AG(平均年龄54.8±12.1岁;女性占44.4%)。最常见的原发癌为胰腺癌,占42.1%(23/54)。34例(62.9%)患者的适应证为姑息治疗,20例(37%)患者为PBD。35例(64.8%)患者梗阻部位在远端,19例(35.1%)患者在近端。EUS-AG的技术成功率为88.7%(47/53)。95.7%(45/47)的患者获得临床成功。术后住院天数中位数为1天。未观察到与操作相关的严重不良事件。在20例行EUS-AG作为PBD的患者中,19例技术成功(95%),94.5%(18/19)的患者获得临床成功。11例患者接受了手术,其中10例成功进行了保留幽门的胰十二指肠切除术(PPPD)(1例术中发现肝转移)。2例患者在PPPD后出现Clavein-Dindo III/IV级并发症,1例在术后30天内死亡。
在术前及姑息治疗中,ERCP失败后EUS-AG安全有效。